TABLE 1.
Baseline host and tumor characteristics of patients immediately prior to administration of ramucirumab/paclitaxel (N = 87)
| Ramucirumab + paclitaxel with preceding ICI (n = 19) | Ramucirumab + paclitaxel without preceding ICI (n = 68) | P | ||
|---|---|---|---|---|
| Host | Age median (IQR), years | 58.2 (54.1, 70.3) | 62.2 (54.4, 67.6) | .64 |
| Male sex, n (%) | 15 (79) | 53 (78) | .92 | |
| ECOG performance status, n (%) | ||||
| 0 | 5 (26) | 31 (46) | .28 | |
| 1 | 11 (58) | 29 (43) | ||
| 2 | 3 (16) | 6 (9) | ||
| 3 | 0 (0) | 2 (3) | ||
| No. of metastatic sites, n (%) | ||||
| <3 | 11 (58) | 50 (74) | .20 | |
| ≥3 | 8 (42) | 18 (26) | ||
| Serum albumin median (IQR), g/dL | 3.9 (3.5, 4.1) | 3.8 (3.5, 4.0) | .98 | |
| Tumor | Primary tumor location, n (%) | |||
| Esophagus | 2 (11) | 16 (24) | .35 | |
| Gastroesophageal junction | 9 (47) | 23 (34) | ||
| Stomach | 8 (42) | 29 (43) | ||
| Grade, n (%) | ||||
| G1 | 8 (42) | 21 (32) | .57 | |
| G2 | 11 (58) | 44 (67) | ||
| G3 | 0 (0) | 1 (1) | ||
| Mismatch repair status, n (%) | ||||
| Proficient | 18 (95) | 24 (89) | -a | |
| Deficient | 1 (5) | 3 (11) | ||
| Unknown | 0 | 41 | ||
| PD-L1 status, n (%) | ||||
| Positive (combined positive score ≥1) | 11 (65) | 3 (21) | -a | |
| Negative (combined positive score <1) | 6 (35) | 11 (79) | ||
| Unknown | 2 | 54 | ||
| HER2 status, n (%) | ||||
| Positive | 4 (21) | 11 (16) | .36 | |
| Negative | 13 (68) | 55 (81) | ||
| Equivocal | 2 (11) | 2 (3) | ||
| Treatment | Prior lines of therapy, n (%) | |||
| 0–2 | 15 (79) | 60 (88) | <.001 | |
| ≥3 | 5 (21) | 8 (12) |
Abbreviations: ICI, immune checkpoint inhibition; PD-L1, programmed death-ligand 1.
a
P value not calculated since the majority of values were unknown for one group.